Keyword: Syros Pharmaceuticals
Blocking the enzyme CDK7 could be a new way to overcome resistant prostate cancer, and one drug is already in trials.
The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.
Syros Pharmaceuticals aims to use small molecules to control the activation and repression of genes. Now, it has raised $50 million in an IPO to get proof-of-concept data.